**
A new vaccine administered during pregnancy has proven to significantly lower the rate of hospital admissions for newborns suffering from respiratory syncytial virus (RSV), with recent studies indicating a remarkable reduction of more than 80%. The UK Health Security Agency (UKHSA) announced this compelling finding, emphasising the vaccine’s critical role in safeguarding infant health during the vulnerable first months of life.
Understanding RSV and Its Impact
Respiratory syncytial virus is a common viral infection that affects a substantial number of infants, particularly in their first year. Each year, over 20,000 babies in the UK are hospitalised due to severe RSV infections, which can lead to serious respiratory distress, feeding difficulties, and in some extreme cases, even fatalities. The virus can manifest as anything from mild cold symptoms to life-threatening lung infections, leaving parents understandably alarmed when their infants show signs of illness.
Dr Conall Watson, the national programme lead for RSV at UKHSA, articulated the distressing experience many parents face when their newborns struggle to breathe. “This is very, very frightening as a parent, frightening with good reason,” he noted, highlighting the urgency of addressing this health concern.
The Introduction of the Vaccine
Since its introduction in 2024, the RSV vaccine has been made available to pregnant women from 28 weeks onwards. Clinical trials demonstrated that the vaccine not only enhances the mother’s immune response but also allows for the transfer of protective antibodies to the infant via the placenta. Consequently, infants born to vaccinated mothers benefit from immediate protection against RSV from birth.
A recent study examining the outcomes of nearly 300,000 births in England—from September 2024 to March 2025—revealed that the vaccine provides nearly 85% effectiveness when administered at least four weeks prior to delivery. Even if the vaccine is given closer to the birth date, some level of protection is still achievable, underscoring the importance of timely vaccination.
Dr Watson encouraged expectant mothers to prioritise vaccination, stating, “If you’ve got a longer interval between when the vaccine gets given and when baby is born, then you get even better protection. Get it on time. But if you can’t, do get vaccinated all the way through the third trimester.”
Hospitalisation Rates and Vaccination Uptake
The study also reported that over 4,500 babies were admitted to hospitals during the evaluation period, with a large proportion of these infants being born to mothers who had not received the RSV vaccine. This stark statistic highlights the vaccine’s crucial role in preventing serious health complications in newborns.
While the uptake of the RSV vaccine among pregnant women in England is approximately 64%, this figure drops to just 53% in London, indicating a potential area for public health interventions. Alongside the RSV vaccine, pregnant women are also advised to receive vaccinations for flu and whooping cough to further protect both themselves and their babies.
Personal Stories Highlight the Urgency
The importance of the RSV vaccine is underscored by personal accounts, such as that of Laine Lewis, whose son Malachi faced life-threatening complications due to RSV prior to the vaccine’s availability. Malachi, now 12, suffered severe repercussions, including brain damage, after contracting the virus as an infant. Lewis emphasised the rarity of such outcomes but strongly advocated for vaccination, stating, “I’d encourage people to take the vaccine for RSV because it will help their child.”
Dr Watson reiterated the vaccine’s potential to significantly improve infant safety during the winter months, urging all pregnant women to consult with healthcare providers regarding vaccination schedules.
Why it Matters
The introduction of the RSV vaccine represents a pivotal advancement in maternal and infant health, offering hope for the prevention of serious respiratory illnesses in newborns. As we witness the impact of this vaccine on hospitalisation rates, it becomes increasingly clear that public health initiatives must focus on improving vaccination uptake, particularly in areas with lower compliance. Protecting our youngest and most vulnerable populations is not merely a matter of individual health; it is a critical public health priority that can save lives and alleviate the burden on healthcare systems. The continued promotion and education surrounding this vaccine could lead to a transformative era in the fight against RSV and other respiratory infections in infants.
